Lexicon Pharma (LXRX) reported Q1 Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.55 -0.64%
Revenue Growth %: -79.9%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
SICP, MNSB, CFFI, More
Revenue Growth %: -79.9%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 Revenue for the quarter came in at $21.1 million versus the consensus estimate of $9.78 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank Names Top Utility Stocks Amid Data Center Growth
- 22nd Century Group reports Q3 revenue up 66% to $4.8M
- Elon Musk Invests $1B In Ellison’s Skydance - Semafor
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
